JP Patent

JP7660604B2 — ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製

Assigned to イーライリリーアンドカンパニー · Expires 2025-04-11 · 1y expired

What this patent protects

Patent listed against lasmiditan-succinate.

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: JP7660604B2
Jurisdiction: JP
Classification: —
Expires: 2025-04-11
Drug substance claim: No
Drug product claim: No
Assignee: イーライリリーアンドカンパニー
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.